Article Information
History
- October 26, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Gerard Godoy-Tena1,
- Anis Barmada2,3,
- Octavio Morante-Palacios1,
- Carlos de la Calle-Fabregat1,
- Ricardo Martins-Ferreira1,
- Anna G. Ferreté-Bonastre1,
- Laura Ciudad1,
- Adolfo Ruiz-Sanmartín4,
- Mónica Martínez-Gallo5,
- Ricard Ferrer4,
- Juan Carlos Ruiz-Rodriguez4,
- Javier Rodríguez-Ubreva1,
- Roser Vento-Tormo2 and
- Esteban Ballestar1,6,*
- 1Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), 08916 Badalona, Barcelona, Spain
- 2Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, United Kingdom
- 3Department of Medical Genetics, University of Cambridge, Cambridge CB2 0QQ, United Kingdom
- 4Intensive Care Department, Vall d’Hebron University Hospital, Shock, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
- 5Immunology Division, Vall d’Hebron University Hospital and Diagnostic Immunology Research Group, Vall d’Hebron Research Institute (VHIR), 08035 Barcelona, Spain
- 6Epigenetics in Inflammatory and Metabolic Diseases Laboratory, Health Science Center (HSC), East China Normal University (ECNU), Shanghai, 200241, China
- ↵*Correspondence: E. Ballestar, E-mail: eballestar{at}carrerasresearch.org
Posted October 26, 2022.
Epigenetic and transcriptomic reprogramming in monocytes of severe COVID-19 patients reflects alterations in myeloid differentiation and the influence of inflammatory cytokines
